[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338278-105":59,"doc-detail-338278-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","overcoming-immunotherapy-resistance-and-inducing-abscopal-effects-with-boron-neutron-immunotherapy-b-nit","Overcoming immunotherapy resistance and inducing abscopal effects with boron neutron immunotherapy (B-NIT)","","Immune checkpoint inhibitors (ICIs) benefit many advanced cancers, yet a substantial portion of patients show no response, making resistance an urgent clinical challenge. Boron neutron capture therapy (BNCT) locally combines boron drugs that accumulate in tumors with neutron irradiation. The study introduces boron neutron immunotherapy (B-NIT), integrating BNCT with anti-PD-1 immune checkpoint blockade in a radioresistant, immunotherapy-resistant B16F10 melanoma mouse model.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/overcoming-immunotherapy-resistance-and-inducing-abscopal-effects-with-boron-neutron-immunotherapy-b-nit/338278/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/overcoming-immunotherapy-resistance-and-inducing-abscopal-effects-with-boron-neutron-immunotherapy-b-nit/338278.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is B-NIT and how is it constructed from BNCT and immunotherapy?","Question",{"text":112,"@type":113},"B-NIT combines BNCT with ICI immunotherapy by pairing boron drugs that selectively accumulate in tumors with neutron irradiation at the tumor site, together with anti-PD-1 treatment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the different treatment groups perform in the B16F10 melanoma mouse model?",{"text":117,"@type":113},"The BNCT group suppressed localized tumors, anti-PD-1 alone did not show tumor suppression, and only the B-NIT group inhibited tumor growth at both BNCT-treated and distant shielded sites.",{"name":119,"@type":110,"acceptedAnswer":120},"What immune or molecular findings support an abscopal, immune-mediated mechanism?",{"text":121,"@type":113},"B-NIT increased intratumoral CD8+ T-cell infiltration and serum HMGB1 levels, with tumor-infiltrating lymphocytes showing elevated CD62L-CD44+ effector memory T cells and CD69+ early-activated T cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338278,1790654954,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Received: 21 May 2024 | Revised: 11 July 2024 | Accepted: 15 July 2024  \nDOI: 10. 1111/cas.16298  \nOR I G I NAL ART I C L E  \nOvercoming immunotherapy resistance and inducing abscopal effects with boron neutron immunotherapy (B-NIT)  \nTakuya Fujimoto1,2 | Osamu Yamasaki3,4 | Noriyuki Kanehira1,2 | Hirokazu Matsushita5 | Yoshinori Sakurai6 | Naoya Kenmotsu7,8 | Ryo Mizuta5,8 | Natsuko Kondo6  | Takushi Takata6 | Mizuki Kitamatsu9 | Kazuyo Igawa2 | Atsushi Fujimura2,10  | Yoshihiro Otani8 | Makoto Shirakawa2 | Kunitoshi Shigeyasu1 | Fuminori Teraishi1 | Yosuke Togashi7  | Minoru Suzuki6 | Toshiyoshi Fujiwara1  | Hiroyuki Michiue2   \n1Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan 2Neutron Therapy Research Center, Okayama University, Okayama, Japan  \n3 Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan 4Department of Dermatology, Shimane University Faculty of Medicine, Izumo, Japan  \n5Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan  \n6Institute for Integrated Radiation and Nuclear Science, Kyoto University, Sennan-gun, Japan  \n7Department of Tumor Microenvironment, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan 8 Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan 9Faculty of Science and Engineering, Kindai University, Higashiosaka, Japan  \n10 Department of Physiology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan  \nCorrespondence  \nHiroyuki Michiue, Neutron Therapy Research Center, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama 700- 8558, Japan.  \nEmail: [hmichiue@md.okayama-u.ac.jp](hmichiue@md.okayama-u.ac.jp)  \nFunding information  \nTakeda Science Foundation, Grant/Award Number: Takeda Science Foundation / 2016049889; Japan Society for the Promotion of Science, Grant/Award Number: Scientific Research KAKENHI / 20K08652, Scientific Research KAKENHI / 21K09176, Scientific Research KAKENHI / 22K08803, Scientific Research KAKENHI / 23K07765 and Scientific Research KAKENHI / 24K12263  \nAbstract  \nImmune checkpoint inhibitors (ICIs) are effective against many advanced malignancies. However, many patients are nonresponders to immunotherapy, and overcoming this resistance to treatment is important. Boron neutron capture therapy (BNCT) is a local chemoradiation therapy with the combination of boron drugs that accumulate selectively in cancer and the neutron irradiation of the cancer site. Here, we report the first boron neutron immunotherapy (B-NIT), combining BNCT and ICI immunotherapy, which was performed on a radioresistant and immunotherapyresistant advanced-stage B16F10 melanoma mouse model. The BNCT group showed localized tumor suppression, but the anti-PD-1 antibody immunotherapy group did not show tumor suppression. Only the B-NIT group showed strong tumor growth inhibition at both BNCT-treated and shielded distant sites. Intratumoral CD8+ T-cell infiltration and serum high mobility group box 1 (HMGB1) levels were higher in the B-NIT group. Analysis of CD8+ T cells in tumor-infiltrating lymphocytes (TILs) showed that CD62L-CD44+ effector memory T cells and CD69+ early-activated T cells were predominantly increased in the B-NIT group. Administration of CD8-depleting mAb to the B-NIT group completely suppressed the augmented therapeutic effects. This  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \n© 2024 The Author(s) . Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of J","cbCaieraRB0ND0Sm","https://ap.wps.com/l/cbCaieraRB0ND0Sm","pdf",24663541,17,"English","# Abstract\n# Introduction\n## PD-1 and immune checkpoint inhibition\n## Clinical outcomes and limitations of dual ICI therapy\n# Methods and study rationale\n# Results: B-NIT drives local and distant control\n# Mechanistic insights: T-cell infiltration and HMGB1","[{\"question\":\"What is B-NIT and how is it constructed from BNCT and immunotherapy?\",\"answer\":\"B-NIT combines BNCT with ICI immunotherapy by pairing boron drugs that selectively accumulate in tumors with neutron irradiation at the tumor site, together with anti-PD-1 treatment.\"},{\"question\":\"How did the different treatment groups perform in the B16F10 melanoma mouse model?\",\"answer\":\"The BNCT group suppressed localized tumors, anti-PD-1 alone did not show tumor suppression, and only the B-NIT group inhibited tumor growth at both BNCT-treated and distant shielded sites.\"},{\"question\":\"What immune or molecular findings support an abscopal, immune-mediated mechanism?\",\"answer\":\"B-NIT increased intratumoral CD8+ T-cell infiltration and serum HMGB1 levels, with tumor-infiltrating lymphocytes showing elevated CD62L-CD44+ effector memory T cells and CD69+ early-activated T cells.\"}]","Overcoming immunotherapy resistance and inducing abscopal effects with boron neutron immunotherapy (B-NIT) | PDF",1790022891,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1765dc4757ca1af9330a72cf2f4554c3.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12a6e36b54d4bc6a98bf20f3c2b3bda2.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de0c2bcbddf3be63e872d5fb1ad41591.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ec330ea17bcbed45908a9b6141aaf04.webp",980,1287]